Logo
x

Search

Subscribe Now

 Finerenone

Bayer Reports the US FDA’s sNDA Acceptance & Priority Review of Finerenone for Heart Failure (HF)

Bayer Reports the US FDA’s sNDA Acceptance & Priority Review of Finerenone for Heart Failure (HF)

  • March 18, 2025
Bayer Submits MAA of Finerenone to Japan’s MHLW for Heart Failure (HF)

Bayer Submits MAA of Finerenone to Japan’s MHLW for Heart Failure (HF)

  • February 14, 2025
Bayer Submits MAA of Finerenone to the EMA for Heart Failure (HF)

Bayer Submits MAA of Finerenone to the EMA for Heart Failure (HF)

  • February 4, 2025
Bayer Reports the P-III (FINEARTS-HF) Study Data of Finerenone to Prevent Heart Failure with Preserved Ejection Fraction

Bayer Reports the P-III (FINEARTS-HF) Study Data of Finerenone to Prevent Heart Failure with Preserved Ejection Fraction

  • August 5, 2024
Bayer to Initiates P-III Study (FINE-ONE) of Finerenone for the Treatment of Chronic Kidney Disease and Type 1 Diabetes

Bayer to Initiates P-III Study (FINE-ONE) of Finerenone for the Treatment of Chronic Kidney Disease and Type 1 Diabetes

  • June 22, 2023
Bayer’s Kerendia (finerenone) Receives NICE Recommendation for Chronic Kidney Disease Associated with Type 2 Diabetes

Bayer’s Kerendia (finerenone) Receives NICE Recommendation for Chronic Kidney Disease Associated with Type 2 Diabetes

  • March 27, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.